homepage  accelmed vision  strategy  team  portfolio  contact    accelmed invests in private and public medical device companies around the world accelmed merges global businesses with promising medical device startups creating significant revenue growth accelmed’s platform model has proven to provide high returns to investors managers and entrepreneurs accelmed invests in private and public medical device companies around the world accelmed merges global businesses with promising medical device startups creating significant revenue growth accelmed’s platform model has proven to provide high returns to investors managers and entrepreneurs accelmed invests in private and public medical device companies around the world accelmed merges global businesses with promising medical device startups creating significant revenue growth accelmed’s platform model has proven to provide high returns to investors managers and entrepreneurs             merging medtech innovation with global commercial platforms    accelmed is an investment firm focused on value creation for medical device companies and technologies accelmed was founded in  by mori arkin and uri geiger and invests in small and midcap private and public companies with its proven track record and large team of accomplished investment professionals accelmed’s vision is to create leading medtech players by merging commercial platforms with small innovative growth companies predominantly from israel                       integrating commercial platforms with innovation and providing growth equity to foster significant value creation   accelmed brings its acumen in medical devices and its dominant presence in israel to the platform model which has already been implemented with great success under the platform model accelmed integrates innovative and marketready medical device technologies into existing commercial companies that are able to effectively distribute and commercialize the new products accelmed makes significant equity investments – or a combination of equity and debt – of between m and m per platform in certain cases in combination with its coinvesting partners investment can be increased to up to m we intend to acquire a significant interest in established medical device companies in the us europe and potentially in china with revenues in excess of m and which have an experienced direct sales force     proceeds of our investments will be used for both organic and inorganic growth through the acquisition and integration of innovative market ready medical device technologies identified and selected by accelmed and the platform company management the acquired israeli startups will serve as ongoing sources for costefficient rd as based on accelmed’s proven experience with israeli rd teams  they are not only innovative but also operate in a faster and more efficient way than their peers overseas     platform case studies endochoice – platform model case study the platform model modus operandi is best illustrated through the merger between peer medical an israeli company and developer of the full spectrum endoscope and endochoice a gastroenterology gi player in atlanta ga which had a solid commercial infrastructure but which lacked innovative products by merging peer into endochoice and the addition of working capital accelmed was able to transform endochoice from a commodity player into a cutting edge technology company the merger carried out in  led to endochoice’s emergence as a leading global gi player with sales above m in  more than doubled since the merger high doubledigit growth and a presence in more than  countries endochoice completed a successful ipo on june  and was sold to boston scientific in october          ois – platform model case study ois is another example of the successful deployment of accelmed’s platform model ois a californiabased ophthalmic imaging systems player acquired medivision the developer of an innovative retinal camera based on israeli defense technology the deal was financed and led by accelmed which held  of ois’s shares postmerger in  within two years ois was sold providing accelmed with an outstanding return                       team  mori arkin cofounder and chairman of the investment committee   mori arkin is one of israel’s most successful life science entrepreneurs he was the principal shareholder and chairman of agis industries  ltd from its establishment until its merger with perrigo in  agis one of the leading generic pharmaceutical companies in israel merged with usbased perrigo in march  in an  million transaction mr arkin has a degree in psychology and philosophy from the tel aviv university  dr uri geiger cofounder and managing partner   uri geiger brings extensive entrepreneurial management and investment knowhow having created and built many successful medical device enterprises until january  dr geiger served as ceo of exalenz bioscience ltd taseexen developer of an innovative breathbased technology for diagnosing liver and gastrointestinal disorders that was acquired from oridion systems today part of covidien and dr geiger took public in  he previously cofounded and was the ceo of galayor networks a developer of optical components sold in  to memscap euronext mems dr geiger is also the founding partner of dragon variation fund one of israel’s first hedge funds which was sold to migdal in  dr geiger worked on wall street during the s where he gained a broad understanding of capital markets and significant experience which he put to use after returning to israel in  dr geiger was formerly an adjunct professor at the recanati business school at tel aviv university where he lectured on private equity and venture capital he is the author of the books startup companies and venture capital tel aviv university press  and from concept to wall street financial times – prentice hall  he earned his doctorate from new york’s columbia university center for law  economics where he majored in global equity markets dr geiger served as a major in the israeli air force  dr irit yaniv md mba general partner   irit yaniv is an experienced and accomplished senior executive in the medtech industry and has held ceo positions with medical device companies impulse dynamics and metacure she plays an important role in leading accelmed’s early stage portfolio companies serving either as chairperson or as an active board member dr yaniv holds an md degree from the bengurion university and an mba from the recanati business school at tel aviv university  ilan ben oren partner  cto   mr ben oren brings more than  years’ experience in rd and management in the medical equipment field  mr ben oren assists accelmed’s portfolio companies in various development tasks prior to joining accelmed he served as the cto of exalenz bioscience ltd taseexen a developer of an innovative breathbased technology for diagnosing liver and gastrointestinal disorders prior to that mr ben oren held various positions from project manager to cto at oridion medical swxoridn earlier in his career he worked as a senior physicist at scitex ltd nasdaqscix and participated for five years in applied research at the laser center of hadassah hospital einkerem and the hebrew university mr ben oren is the author of more than  patents and patent applications in the field of medical technologies and electrooptics he holds a master’s degree in applied physics and the science of materials summa cum laude from the hebrew university of jerusalem  amir blatt partner   amir blatt brings wide experience in both the investment and medical device fields prior to joining accelmed mr blatt was an analyst at goren capital group advising investors ta companies and the government of israel on ma activity previously mr blatt held several sales and marketing positions with dover medical devices the jj distributor of diagnostics equipment in israel mr blatt graduated as a biotechnology engineer from the technionisrael institute of technology in haifa and holds an mba from the recanati school of management at tel aviv university  dr guy ohad chief medical officer   dr guy ohad is a radiologist with rich experience in the field of technology and medical devices his most recent positions include ceo at pop medical solutions a woman’s health company developing a minimal invasive device for treatment of pelvic organ prolapse before this he was vp of clinical and business development of the cr product line at orex a csh company former kodak in addition he served as a consultant to several medical device companies and served as clinical advisor at medica vc dr ohad holds a md from tel aviv university  dr susan alpert md phd chief regulatory officer   susan alpert formerly chief regulatory officer of medtronic is accelmed’s senior regulatory and clinical advisor she provides services to accelmed on a part time  basis working with accelmed portfolio companies as well as assisting accelmed in reviewing and evaluating investment opportunities dr alpert has held the positions of senior vice president and chief regulatory officer at medtronic until  and had a similar role at cr bard nysebcr before joining medtronic she held a number of positions with the fda including as director of the fda’s office of device evaluation dr alpert holds md and phd in infectious diseases from the nyc school of medicine   nadav shimoni associate   madav shimoni completed his medical studies at the ben gurion university bgu of the negev in beer sheva mr shimoni previously served as a project manager at an idf elite technological unit gaining significant experience in developing and designing complex mechanical elements in addition he is an anatomy teaching assistant at the medical school for international health msih – a collaboration between bgu and columbia university medical center he also engages in active volunteering work including medical workshops for populations in need  nir gilad analyst   nir gilad is involved with investment analysis and ongoing portfolio management prior to accelmed mr gilad worked at the israeli ministry of defense as a project finance analyst leading the national project of relocating the idf’s units to the south of israel previously he served as a financial analyst at the idf’s elite technology unit leading the unit’s economic analysis awarded with an honor for excellence mr gilad is an associate mentor at the global business studies program at coller school of management at tel aviv university and he holds a ba in economics and an mba both from tel aviv university  dr gilad rotem analyst   dr rotem holds an md degree from the technionisrael institute of technology in haifa israel as well as a bsc from tel aviv university in industrial engineering and another in biology in addition mr rotem was formerly professional longdistance triathlete who has participated in numerous international competitions mr rotem’s strong academic background and accomplishments in professional sports give him a unique perspective on health and athletics making him a valued asset to the accelmed team   executives network accelmed enjoys close collaboration with a network of seasoned executives who have built led and sold companies for billions of dollars these executives assist accelmed in identifying and analyzing potential opportunities and may serve in key leadership roles in future platform companies             the portfolio reflects a diversity of strategies employed in accelmed’s first and second funds   platforms  cogentix   cogentix nasdaqcgnt is a us based global urology focused company its main areas of activity are in overactive bladder oab advanced endoscopy systems and urethral bulking agents  httpwwwcogentixmedicalcom    endochoice sold   a global platformtechnology company focused on gastrointestinal gi endoscopy endochoice has merged with peer medical an israeli company which developed of a unique endoscopy technology to form a leading player in the gi industry endochoice is headquartered in alpharetta georgia with its rd center based in israel endochoice completed a successful ipo in june  and was sold to boston scientific in october  httpwwwendochoicecom  ophthalmic imaging systems sold   ophthalmic imaging systems ois is a leading provider of ophthalmic imaging and informatics solutions ois was the first investment of accelmed closed q and was sold two years later q to merge healthcare nasdaq merge httpwwwcanadianpharmacynet” target”blank”httpwwwcanadianpharmacynet  volcano sold   through its multimodality platform volcano corporation nasdaq volc is the global leader in intravascular imaging for coronary peripheral and physiology applications accelmed took a role of an active investor in the company which contributed to a successful acquisition by philips only a few months later httpwwwvolcanocorpcom   targeted innovation  corvia   corvia is developing the first transcatheter device to treat congestive heart failure chf the company’s innovative iasd™ interatrial shunt device system is designed to relieve increased left atrial pressure httpcorviamedicalcom  valcare medical   valcare medical was founded in  and is dedicated to designing developing and commercializing devices and accessories for minimally invasive treatment of heart valve disease httpwwwvalcaremedicalcom  digma   digma medical is an exciting new medical device startup that is focused on developing innovative solutions to metabolic diseases  sonivie   sonivie is developing an advanced denervation solution to treat pulmonary hypertension   incubator  eximo medical   eximo medical ltd is an early stage startup company founded in  the company is developing a novel medical device based on a single use hybrid catheter for various medical applications that require precise and safe material removal these applications have substantial and growing markets httpwwweximomedicalcom  memic   memic innovative surgery ltd is an early stage robotic company that develops an innovative surgical robot the surgical robot is based on a novel design which enables intuitive control and a new surgical approach for laparoscopic procedures  nitinotes   nitinotes is developing advanced nonsurgical bariatric solutions  revamp   revamp is offering an innovative temporary catheter for acute heart failure ahf primarily targeting diuretic resistance patients   venture capital  cartiheal   cartiheal is the developer of proprietary biocompatible and biodegradable offtheshelf implants for cartilage and bone regeneration cartiheal’s acellular implant is arthroscopically pressfit within a cartilage or osteochondral defect in a singlestage procedure and supports vessels formation followed by rapid invasion and adhesion of bone marrow mesenchymal stem cells the ce marked implant has significant loadbearing capability allowing patients faster rehabilitation httpwwwcartihealcom  endospan   endospan ltd is a vcbacked clinicalstage medical device startup developing a novel endovascular system intended to provide the next generation in endovascular aortic aneurysm repair evar endospan’s system aims to achieve a much smaller crossing profile compared with contemporary devices the system is intended for unilateral and purely percutaneous approach thus simplifying and significantly shortening the procedure httpwwwendospancom  nitiloop   nitiloop is dedicated to the development of cutting edge vascular support microcatheters our technology provides superior operatorcontrolled positioning and support in multiple applications nitiloop brings to the market ‘first choice’ products to overcome difficult lesions httpwwwnitiloopcom  picardia   picardia ltd is a medical device startup company developing a novel low profile catheter for the treatment of aortic stenosis the company’s proprietary technology is based on delivering mechanical impact for creating fractures in valve calcifications without injuring the surrounding soft tissue this treatment which only takes several seconds is intended to increase the valve effective orifice area without the need to replace the valve httpwwwpicardiacom   contact us office  madison avenue suite b new york ny  tel  israel office  hachoshlim st th floor herzliya pituach  tel  email infoaccelmedcom     accelmed growth partners lp top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active accelmed growth partners lp • herzliya pituach l • private equity how do i update this listing accelmed growth partners is based out of herzliya pituach whalewisdom has at least  dg filings in our database for accelmed growth partners the firm last filed a form d notice of exempt offering of securities on  the filing was for a pooled investment fund private equity fund the notice included securities offered of pooled investment fund interests summary dg insider form  form d  create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from accelmed growth partners lp enter your email address below and choose submit your email cancel contact info accelmed growth partners lp  hachoshlim street th floor herzliya pituach l     business phone  recent sec filings da filed on   filed on  sc d filed on  da filed on  d filed on  current dg holdings stock sector shares held market value rank source source date cogentix medical cgnt health care    d  schedule d and g events since  subscription required form   nonderivative insider transactions since  loading form d filings form d is a form to be used to file a notice of an exempt offering of securities with the securities and exchange commission form d contains basic information about the offering and the company form d filings filing date form type industry group securities offered total offering amount total amount sold total remaining  da pooled investment fund private equity fund pooled investment fund interests     da pooled investment fund private equity fund pooled investment fund interests     d pooled investment fund private equity fund pooled investment fund interests    other issuers in filings name address no other issuers related parties included in filings name address relationship agp ltd general partner of the gp accelmed growth partners subscription required promoter gp lp general partner accelmed growth partners subscription required promoter moshe arkin subscription required director uri geiger subscription required director elevate your investments try it for free   cogentix receives  million infusion of capital from accelmed growth partners  startribunecom continue to site snapshots star tribune a severe thunderstorm rolled past lake harriet towards downtown minneapolis photo david jolesstar tribune buy print buy twitter facebook linkedin pinterest share about about startribune more from the homepage prev senate votes to open health bill debate but nothing is certain bca warrant in damond killing says woman slaps squad car twin cities under severe thunderstorm watch until  pm baby deliveries to end at st josephs hospital in st paul justice dept rules intensify crackdown on sanctuary cities what senators really think hot mic reveals fears that trump is crazy im worried delasalle guard kalscheur verbally commits to minnesota fan who prompted peter framptons treasure island meltdown laments her role hormel launches snack packs with meat cheeses and nuts how jerry kill ended up coaching in the big ten again why we get brain freeze when eating ice cream — and tips for avoiding it next business  cogentix receives  million infusion of capital from accelmed growth partners accelmed transaction helps clean up cogentixs balance sheet and gives it cash to add to portfolio of products  by patrick kennedy star tribune september   — pm text size comment share tweet email print more share on share on linkedin share on google share on pinterest copy shortlink purchase order reprint minnetonka medical device maker cogentix medical has received a  million equity investment to help the company grow and add more products cogentix which makes devices for urology gynecology bariatric medicine and other uses entered into the securities purchase agreement with accelmed growth partners lp a new york and israelbased private equity investment firm that specializes in building medical device companies cogentix said on wednesday under terms of the deal accelmed will purchase more than  million shares or  million worth of cogentix stock for  per share — a  percent premium over the closing price on tuesday and a  percent premium on the average price over the last  days cogentix shares jumped  percent on the news closing wednesday at  up  cents as part of the deal cogentix will convert debt and accrued interest owed to one of its directors lewis pell into common shares the company owes a total of  million to pell — who waged and won a proxy fight earlier in the year that resulted in a change of ceos debt owed to pell will be converted into common stock at a price per share of  darin hammers the new president and ceo of cogentix said the deal cleans up the company’s balance sheet by erasing the company’s longterm debt while giving the company nearly  million in cash “this gives us resources to go out and identify innovative products to add to our lineup” hammers said accelmed specializes in taking marketready medical devices and improving their marketing and product distribution after the transaction pell and accelmed will be the largest shareholders in cogentix respectively controlling  percent and  percent of cogentix’s outstanding shares pell and accelmed also have entered into a voting agreement to elect two new board members nominated by accelmed to cogentix’s existing sixperson board of directors this changes the composition of cogentix’s board for the second time this year the first after pell won his proxy fight in may one of the two new board members — and the next chairman of cogentix’s board — will be uri geiger a cofounder and managing partner of accelmed the other board nominee is homi shamir former ceo of given imaging a medical device company based in israel that was acquired by covidien in february  geiger and accelmed are committed to working with hammers and the rest of cogentix’s current leadership team the companies said “we  believe that with the appropriate resources and a wellplanned business development strategy cogentix could expand into being one of the leaders in the urology marketplace” said geiger in a statement cogentix medical is the result of a december  merger between two small medical device companies uroplasty inc and new jerseybased visionsciences inc where pell was cofounder and chairman during the  months ending june  cogentix had  million in revenue and an operating profit excluding onetime costs of  million after the announcement of the deals roth capital partners analyst chris lewis raised his recommendation on cogentix from “neutral” to “buy” and raised the month price target for shares of cogentix to  per share “the proposed transactions would transform cogentix’s capital structure an overhang that has limited stock upside and new investor interest in the name since the uroplastyvision sciences merger” lewis wrote shareholders are expected to vote and approve the changes by midnovember   patrickkennedystartribunecom  pkennedystrib view comments read our comment standards startribunecom welcomes and encourages readers to comment and engage in substantive mutually respectful exchanges over news topics commenters must follow our terms of use keep it civil and stay on topic no profanity vulgarity racial slurs or personal attacks comments with web links are not permitted comments that violate the above will be removed repeat violators may lose their commenting privileges on startribunecom comments will be reviewed before being published powered by livefyre  more from star tribune fan who prompted peter framptons treasure island meltdown laments her role what senators really think hot mic reveals fears that trump is crazy im worried how jerry kill ended up coaching in the big ten again twin cities under severe thunderstorm watch until  pm bca warrant in damond killing says woman slaps squad car fake twin cities street signs warn of easily startled police heinrich confesses to abducting killing jacob wetterling that day failure to accept responsibility leads to robinsons firing by u a note to readers in court loved ones confront awful truth of jacobs last hours rite aid and klatencor skid while citigroup staples climb deere shares rise on deal to buy german road construction company polaris industries to buy transamerican auto parts for  million correction abbottst jude acquisition story company news allete enteromedics announce executive retirements more from business variety  minutes ago new york citys transit agency unveils m subway plan the head of new york citys transit agency on tuesday unveiled an  million plan to stabilize the beleaguered subway system and promised that riders would see progress within the next year national  minutes ago senate votes to open health bill debate but nothing is certain prodded by president donald trump a bitterly divided senate voted at last tuesday to move forward with the republicans longpromised legislation to repeal and replace obamacare there was high drama as sen john mccain returned to the capitol for the first time after being diagnosed with brain cancer to vote national  minutes ago court nixes rifle target makers defamation suit against nbc a rifle target maker missed its mark when it said in a lawsuit that nbc mischaracterized its exploding targets as bombs a federal appeals court ruled tuesday national  minutes ago the latest capitol police arrest  in demonstrations the latest on the effort by congressional republicans to pass a health care bill all times local business  minutes ago chipotle says employee worked while ill at va location chipotle says it believes an employee was working while sick at a virginia location where dozens of customers reported becoming ill earlier this month with what health officials think was norovirus top stories senate votes to open health bill debate but nothing is certain  minutes ago bca warrant in damond killing says woman slaps squad car  minutes ago twin cities under severe thunderstorm watch until  pm  minutes ago most read hormel launches snack packs with meat cheeses and nuts • business m investors take profits from record stock run after mixed q results • business wisconsin employees lining up for implantable microchips • business schwans acquires two more frozen pizza companies • business sports franchises flock to minneapolis marketing company • business world surprisingly elite families in isolated north korea actually use gmail facebook itunes australian minister quits cabinet because he might be italian nation trumps boy scouts speech broke with  years of presidential tradition wisconsin employees lining up for implantable microchips politics senate votes to open health bill debate but nothing is certain manafort talks with senate panel about russia meeting while another subpoenas him markets get quote symbol lookup  minute delay last updated twins bellingers home run sends twins to loss back to  on the season twins get garcia deal done by sending atlanta a different prospect vikings hello goodbye vikings rookie seeks to fill big shoes on special teams murray injury giving other backs upper hand for playing time mn united minnesota united stadium name goes global in deal with allianz bruce arena blends intense demands with humor to lead us celebrities princes william harry remember their final call with diana home alone actor john heard dies at  following back surgery super bowl lii at msp airport the day after the super bowl will be a super test minnesota super bowl volunteer center to open on nicollet mall poll poll should the twins be buyers or sellers as the trading deadline top workplaces was your company one of the top workplaces of  featured gallery russian ballet summer dance camp  photos the academy of russian ballet runs a summer intensive dance camp from july  featured video fly over the new st croix river bridge  set to open in august the new bridge is over a mile long and will allow over  magazine an act of racism stunned delano now the town is fighting back beauty and the bees aveda heiress adds buzz to fathers dream of saving world   startribune all rights reserved accelmed growth partners lp  pooled investment fund accelmed growth partners formdscom  sec filings of fundraisings and investments in hedge funds private equity firms startups and growing companies formdscom newest filter local accelmed growth partners lp industry pooled investment fund see others in industry address  hachoshlim street  th floor herzliya pituach l phone  filings date filingtype reported sold incremental cash type exemptions link to raw filing  amended   other b c c sec link  amended   other b c c sec link  new   other b c c sec link directors and executives current and past name role gp lp general partner accelmed growth partners promoter agp ltd general partner of the gp accelmed growth partners promoter moshe arkin director uri geiger director cogentix medical grabs  million from accelmed employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       cogentix medical grabs  million from accelmed tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs cogentix medical enters into definitive agreement for  million equity investment  proceeds to provide resources to execute urology focused business development strategy  proposed equity investment at  premium to market  all current outstanding debt to be converted into common shares minneapolis sept   prnewswire  cogentix medical inc nasdaq cgnt a medical device company that develops manufactures and markets innovative proprietary products for the urology market today announced that it has entered into a securities purchase agreement with accelmed growth partners lp  under the terms of the securities purchase agreement accelmed would purchase  million of cogentix medical common stock from the company at  per share a  premium over the closing price of the stock on september   and a premium of  over the average closing price over the last  days  the securities purchase agreement is subject to various closing conditions including approval by the shareholders of cogentix medical  accelmed is a premier capital resource for the medical device industry and is based in new york ny and hertzeliya israel  cogentix would apply the proceeds to working capital as well as the implementation of a business development strategy to acquire growth technologies addressing the urology marketas a condition to accelmed closing the equity investment the company will convert into common shares all the outstanding debt and accrued interest owed to lewis c pell one of the companys class i directors  cogentix currently owes a total of  million  million of principal and  million of accrued interest to mr pell  the company and mr pell have entered into a definitive agreement under which the debt owed by cogentix to mr pell will be converted into cogentix common stock at a price per share of  immediately prior to closing the accelmed securities purchase agreement  the agreement also provides that simultaneously with the conversion of such debt all outstanding warrants to purchase cogentix common stock that are held by mr pell will be cancelled the agreement with mr pell is subject to approval of the shareholders of cogentix medicalthe proposed transaction with accelmed has the ability to transform cogentix medical said darin hammers president and ceo of cogentix medical  while our team has been successfully executing our sales strategy and building our business in the urology market we have been resource constrained in terms of providing our sales organization with additional products to bring to our growing customer base  accelmed is one of the worlds leading private equity firms focused on the medical device industry and as israels largest medtech investor has a proven track record of integrating israeli technologies into established us medtech companies  accelmed believes the cogentix platform provides an excellent foundation from which to build a broad based leader providing innovative cost effective and clinically proven solutions to the growing urology marketplace  overall the proposed transactions significantly increase our cash resources eliminate all of our outstanding debt and dramatically improve our capital structure all at valuations that are  higher than what the market is currently awarding our companyupon closing of the proposed transactions there would be approximately  million shares of common stock outstanding of which mr pell would own approximately  and accelmed would own approximately   the current debt and accrued interest outstanding of  million would be eliminated and cogentix would have approximately  million of cash and marketable securities  in addition the terms of the proposed transaction call for accelmed to have the right to nominate two members to the cogentix medical board of directors which currently has six members  one of these directors would be uri geiger who will become chair of the cogentix board mr geiger cofounded accelmed in  and is currently a managing partner of accelmed mr geiger has extensive entrepreneurial management and investment expertise having created and developed many successful medical device companiesthe board of directors of cogentix medical established a special committee of the board comprised solely of independent directors to review these transactions and provide a recommendation to the full board  the special committee engaged duff  phelps llc to serve as its independent financial advisor and to provide an opinion in connection with the proposed transactions  the special committee retained duff  phelps based on duff  phelps qualifications reputation and experience in providing fairness opinions and its experience in valuing companies in the medical device industry duff  phelps has rendered its opinion that the financial terms of the proposed transactions taken as a whole are fair to the unaffiliated public stockholders of the company  the special committee recommended to the full board that it approve the transactions and the cogentix medical board of directors has unanimously approved the transactionswe have admired the revenue growth of cogentix medical under the leadership of darin and his team and believe that with the appropriate resources and a wellplanned business development strategy cogentix could expand into being one of the leaders in the urology marketplace said mr geiger  as a reflection of our confidence in the management team as well as the potential for the company we have agreed to make this investment at a premium to the current market price and look forward to working with the board and management to execute on a shared vision for cogentixadditional information about the transaction and where to find itthe proposed transactions will be submitted to the shareholders of cogentix medical for their approval  the shareholders will be asked to approve the securities purchase agreement and the issuance of shares to accelmed and mr pell in connection with that approval cogentix will file with the securities and exchange commission the sec a proxy statement containing information about the proposed transactions  shareholders are urged to read the proxy statement when it becomes available because it will contain important information  shareholders will be able to obtain a free copy of the proxy statement as well as other filings containing information about cogentix without charge at the secs website wwwsecgov or by calling sec  copies of the proxy statement and other filings with the sec can also be obtained without charge by directing a request to brett reynolds senior vice president and chief financial officer cogentix medical inc  feltl road minnetonka mn  this press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities to be issued as a result of the proposed transactions  the securities to be issued in connection with the proposed transactions have not been registered under the securities act of  as amended or state securities laws and may not be offered or sold absent registration with the sec or an applicable exemption from such registration requirements participants in the solicitationcogentix and some or all of its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from cogentix shareholders in respect of the proposed transactions  information regarding the directors and executive officers of cogentix is contained in the proxy statement for our  annual meeting of shareholders which was filed with the sec on april    additional information regarding the interests of such potential participants will also be included in the proxy statement when it becomes available about cogentix medicalcogentix medical inc headquartered in minnetonka minnesota with additional operations in new york massachusetts the netherlands and the united kingdom is a global medical device company  we design develop manufacture and market products for flexible endoscopy with our unique product lines featuring a streamlined visualization system and proprietary sterile disposable microbial barrier known as endosheath technology providing users with efficient and cost effective endoscope turnover while enhancing patient safety  we also commercialize the urgent® pc neuromodulation system an fdacleared device that delivers percutaneous tibial nerve stimulation ptns for the officebased treatment of overactive bladder oab  oab is a chronic condition that affects approximately  million us adults  the symptoms include urinary urgency frequency and urge incontinence  we also offer macroplastique® an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency  for more information on cogentix medical and our products please visit us at wwwcogentixmedicalcom cgntg for further information cogentix medical inc brett reynolds svp and cfoevc group doug sherkbrian moore investorscautionary statements related to forwardlooking statementsthis press release includes forwardlooking statements  these forwardlooking statements generally can be identified by the use of words such as anticipate expect plan could may will believe estimate forecast goal project and other words of similar meaning  forwardlooking statements in this press release include but are not limited to statements about the benefits of the proposed transactions expected levels of continuing debt expected revenue growth rates the anticipated timing of cash flow breakeven from operations and cash flow positive from operations and our plans objectives expectations and intentions with respect to future operations products and services  each forwardlooking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement  applicable risks and uncertainties include among others the effects of industry economic or political conditions outside of our control the failure to appropriately apply the proceeds from the proposed transactions or to realize the benefits of the reduction in our debt or delay in realization thereof operating costs and business disruption following completion of the transaction transaction and related costs actual or contingent liabilities the adequacy of our capital resources and the risks identified under the heading risk factors in the annual report on form k for the fiscal year ended march   filed with the sec on june   our transition report on form k for the transition period from april   through december   as well as our subsequent quarterly reports on form q and other information filed by us with the sec  we caution investors not to place considerable reliance on the forwardlooking statements contained in this presentation  you are encouraged to read our filings with the sec available at wwwsecgov for a discussion of these and other risks and uncertainties the forwardlooking statements in this presentation speak only as of the date of this release and we undertake no obligation to update or revise any of these statements  our business is subject to substantial risks and uncertainties including those referenced above  investors potential investors and others should give careful consideration to these risks and uncertainties to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasescogentixmedicalentersintodefinitiveagreementformillionequityinvestmenthtmlsource cogentix medical inc read at biospacecom related news healthcare industry leader kenneth a samet joins cogentix medical board of directors investors wait patiently for gilead gild and its ceo to make a ma for growth and to get out of share slump cogentix medical to change fiscal year mylan myl rebuffs rumors ceo will step down cogentix medical names former uroplasty upi exec as new ceo neurophage transforms into proclara bags  million and and launches phase ib alzheimer’s trial cogentix medical reports fourth quarter and full year fiscal  results parexel prxl loses  million in value in one day after disclosing possible misappropriation of corporate funds cogentix medical reports  percent q revenue growth how gilead gild can make another  billion every year please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • cogentix medical   • biotechpharma  finance • medical devices • medical dev  diag  finance                 accelmed skip to main content menu home about projectresults partners med programme investors fora softland in mediterranean events pressfact sheets news newsletter media kit contactbarcelona activa bic of attika promos technology park ljubljana aster anima investment network partners login documents project objective is to accelerate the growth of med smes through a transnational support service to improve access to finance to international markets and to specific advice to growth learn moreorcontact us news visit the news final joint capitalisation event in brussels tuesday march   accelmed project will be presenting the results at the final joint capitalisation event in brussels final newsletter is out thursday march   we have published a final newsletter which presents higlights and accomplishments of accelmed pr about accelmed accelmed is a project developed from previous projects devoted to foster economic development in the mediterranean area through supporting smes moremissionaccelmed will taking the previous med funded projects as a starting point aim at improving the capabilities of the mediterranean smes to grow more partners experiences the consortium which consists of five project partners was sussesfull in obtaining cofinancing from the med programme for the implementation of accelmed more project partners barcelona activa barcelona activa is the executive tool of the economic development policies of the barcelona city council bic of attika a nonprofit organization having as main mission to support the competitiveness and promote business innovations in smes promos the special agency of the milan chambers of commerce is dedicated to the promotion of international activities technology park ljubljana a leading entity in the development of innovative and knowledge based entrepreneurship in slovenia aster the consortium established in  with the aim to support the economic growth of the emiliaromagna productive system anima investment network anima investment network is a multicountry platform supporting the economic development of the mediterranean accelmed growth partners lp d filing  insider monkey companies  see all hedge funds  see all insiders  see all institutional investors  see all click here to see all results for sorry no results has been found matching your query adblocker detected dear valued visitor we have noticed that you are using an ad blocker software although advertisements on the web pages may degrade your experience our business certainly depends on them and we can only keep providing you highquality research based articles as long as we can display ads on our pages to view this article you can disable your ad blocker and refresh this page or simply login we only allow registered users to use ad blockers you can sign up for free by clicking here or you can login if you are already a member home  insider trading  latest d and g filings  d filing  filing details accession number  form type d filing publication date   filed by accelmed growth partners lp company cogentix medical inc nasdaqcgnt filing date  sec url d filing ownership summary please notice the below summary table is generated without human intervention and may contain errors please refer to the complete filing displayed below for exact figures name sole voting power shared voting power sole dispositive power shared dispositive power aggregate amount owned power percent of class                               filing cusip no a    d   page  of  pages      united states securities and exchange commission washington dc      schedule d rule d under the securities exchange act of  amendment no         cogentix medical inc name of issuer common stock  par value title of class of securities a  cusip number uri geiger accelmed growth partners lp  hachoshlim street th floor herzliya pituach israel   name address and telephone number of person authorized to receive notices and communications november   date of event which requires filing of this statement     if the filing person has previously filed a statement on schedule g to report the acquisition that is the subject of this schedule d and is filing this schedule because of §§ dle dlf or dlg check the following box  ☐     note schedules filed in paper format shall include a signed original and five copies of the schedule including all exhibits see §d for other parties to whom copies are to be sent        the remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page the information required on the remainder of this cover page shall not be deemed to be filed for the purpose of section  of the securities exchange act of  act or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act however see the notes       cusip no a    d   page  of  pages        names of reporting persons irs identification nos of above persons entities only   accelmed growth partners lp     check the appropriate box if a member of a group see instructions a  ☐        b  ☒       sec use only       source of funds see instructions   oo     check if disclosure of legal proceedings is required pursuant to items d or e  ☐       citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power    shares         shared voting power    shares         sole dispositive power    shares       shared dispositive power    shares   aggregate amount beneficially owned by each reporting person    shares   check if the aggregate amount in row  excludes certain shares see instructions  ☐     percent of class represented by amount in row       type of reporting person see instructions   pn   based upon  shares of common stock par value  per share of cogentix medical inc outstanding as of november   as provided by cogentix medical inc cusip no a    d   page  of  pages        names of reporting persons irs identification nos of above persons entities only   accelmed growth partners gp lp     check the appropriate box if a member of a group see instructions a  ☐        b  ☒       sec use only       source of funds see instructions   af     check if disclosure of legal proceedings is required pursuant to items d or e  ☐       citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power    shares         shared voting power    shares         sole dispositive power    shares       shared dispositive power    shares   aggregate amount beneficially owned by each reporting person    shares   check if the aggregate amount in row  excludes certain shares see instructions  ☐     percent of class represented by amount in row       type of reporting person see instructions   pn   based upon  shares of common stock par value  per share of cogentix medical inc outstanding as of november   as provided by cogentix medical inc cusip no a    d   page  of  pages        names of reporting persons irs identification nos of above persons entities only   accelmed growth partners agp ltd     check the appropriate box if a member of a group see instructions a  ☐        b  ☒       sec use only       source of funds see instructions   af     check if disclosure of legal proceedings is required pursuant to items d or e  ☐       citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power    shares         shared voting power    shares         sole dispositive power    shares       shared dispositive power    shares   aggregate amount beneficially owned by each reporting person    shares   check if the aggregate amount in row  excludes certain shares see instructions  ☐     percent of class represented by amount in row       type of reporting person see instructions   oo   based upon  shares of common stock par value  per share of cogentix medical inc outstanding as of november   as provided by cogentix medical inc cusip no a    d   page  of  pages        names of reporting persons irs identification nos of above persons entities only   accelmed growth partners management ltd     check the appropriate box if a member of a group see instructions a  ☐        b  ☒       sec use only       source of funds see instructions   oo     check if disclosure of legal proceedings is required pursuant to items d or e  ☐       citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power    shares         shared voting power    shares         sole dispositive power    shares       shared dispositive power    shares   aggregate amount beneficially owned by each reporting person    shares   check if the aggregate amount in row  excludes certain shares see instructions  ☐     percent of class represented by amount in row       type of reporting person see instructions   oo   based upon  shares of common stock par value  per share of cogentix medical inc outstanding as of november   as provided by cogentix medical inc cusip no a    d   page  of  pages        names of reporting persons irs identification nos of above persons entities only   uri geiger     check the appropriate box if a member of a group see instructions a  ☐        b  ☒       sec use only       source of funds see instructions   af     check if disclosure of legal proceedings is required pursuant to items d or e  ☐       citizenship or place of organization   israel number of shares beneficially owned by each reporting person with             sole voting power    shares         shared voting power    shares         sole dispositive power    shares       shared dispositive power    shares   aggregate amount beneficially owned by each reporting person    shares   check if the aggregate amount in row  excludes certain shares see instructions  ☐     percent of class represented by amount in row       type of reporting person see instructions   in   based upon  shares of common stock par value  per share of cogentix medical inc outstanding as of november   as provided by cogentix medical inc cusip no a    d   page  of  pages  schedule d item  security and issuer this statement relates to the common stock  par value the common stock of cogentix medical inc the issuer having its principal executive offices at  feltl road minnetonka mn  item  identity and background this statement is being filed by a    accelmed growth partners lp the fund b    accelmed growth partners gp lp the gp c    accelmed growth partners agp ltd the gpgp d    accelmed growth partners management ltd the management company and e    uri geiger the controlling member and managing partner of the gpgp and the controlling shareholder and managing partner of the management company the persons named in this item  are referred to individually herein as a reporting person and collectively as the reporting persons the reporting persons have entered into a joint filing agreement dated as of the date hereof a copy of which is filed with this schedule d as exhibit  which is incorporated herein by reference pursuant to which the reporting persons have agreed to file this statement jointly in accordance with the provisions of rule dlk under the act the address of the principal business office of the reporting persons is accelmed growth partners lp  hachoshlim street th floor herzliya pituach israel  the principal business of the fund is to invest in medical device companies the principal business of the gp is to act as the sole general partner of the fund the principal business of the gpgp is to act as the sole general partner of the gp the principal business of the management company is to manage the fund the principal business of uri geiger is to manage the fund and affiliated entities during the five years prior to the date hereof none of the reporting persons have been convicted in a criminal proceeding or have been a party to a civil proceeding ending in a judgment decree or final order enjoining future violations of or prohibiting or mandating activities subject to federal or state securities laws or finding any violation with respect to such laws cusip no a    d   page  of  pages  the fund and the gp are cayman island exempted limited partnerships the gpgp and the management company are cayman island private limited companies uri geiger is an israeli citizen item  source and amount of funds or other consideration the fund purchased  shares the shares of common stock at  per share for an aggregate purchase price of  million pursuant to the purchase agreement as defined below the purchase agreement is more particularly described below under item  of this statement the working capital of the fund was the source of the funds for the shares no part of the purchase price of the shares was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring holding trading or voting the shares item  purpose of transaction the fund acquired the shares for investment purposes depending on market conditions its continuing evaluation of the business and prospects of the issuer and other factors the fund and other reporting persons may dispose of or acquire additional shares of the issuer the issuer entered into a securities purchase agreement the purchase agreement with the fund on september   pursuant to the terms of the purchase agreement the fund purchased the shares from the issuer the share issuance on november   the closing date in connection with the purchase agreement on september   the issuer and lewis c pell pell entered into a note exchange agreement the note exchange agreement pursuant to the terms of the note exchange agreement the issuer and pell agreed to convert into shares of common stock all of the outstanding principal amount and accrued interest on certain notes held by pell the notes under the terms of the note exchange agreement the entire outstanding principal amount and all accrued interest on the notes was converted into  shares of common stock at a price per share of  on the closing date also pursuant to the note exchange agreement all of the outstanding warrants held by pell the warrants entitling pell to purchase shares of common stock were cancelled on the closing date in connection with the purchase agreement and the note exchange agreement on september   the fund and pell entered into a voting agreement the voting agreement pursuant to the terms of the voting agreement each of the fund and pell agreed to vote their shares of the issuers common stock for the other partys nominees to the issuers board of directors the board and each of the fund and pell are entitled to nominate two directors uri geiger and nachum shamir the initial nominees of the fund were appointed as members of the board on november   upon the closing of the share issuance the initial nominees of pell were pell and howard zauberman who were incumbent directors of the issuer prior to the closing of the share issuance as a result of the share issuance and the transactions contemplated by the note exchange agreement the transactions the fund and pell own or control a majority of the outstanding common stock as a result of the voting agreement the issuer qualifies as a controlled company under nasdaq rule c and is therefore exempt from certain corporate governance requirements under the nasdaq rules cusip no a    d   page  of  pages  in addition in connection with the purchase agreement the issuer entered into a registration rights agreement the registration rights agreement with the fund and pell on the closing date pursuant to which the issuer agreed upon demand by the fund to file a registration statement with the sec covering the resale of the shares issued pursuant to the terms of the purchase agreement and the note exchange agreement also under the purchase agreement the issuer agreed that following the closing date and upon demand by the fund the issuer will take all corporate actions necessary including taking commercially reasonable efforts to obtain stockholder approval to amend and restate the i amended and restated bylaws of the issuer and ii the amended and restated certificate of incorporation of the issuer the foregoing descriptions of the purchase agreement note exchange agreement the voting agreement and the registration rights agreement do not purport to be complete and are qualified in their entirety by the full text of the agreements copies of which are filed as exhibit  exhibit  exhibit  and exhibit  to this schedule d each of which is incorporated by reference into this item  except as set forth above none of the reporting persons has any present plans which relate to or would result in a    the acquisition by any person of additional securities of the issuer or the disposition of securities of the issuer b    an extraordinary corporate transaction such as a merger reorganization or liquidation involving the issuer or any of its subsidiaries c    a sale or transfer of a material amount of assets of the issuer or of any of its subsidiaries d    any change in the present board of directors or management of the issuer including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board e    any material change in the present capitalization or dividend policy of the issuer f    any other material change in the issuers business or corporate structure g    changes in the issuers charter bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person h    causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an interdealer quotation system of a registered national securities association cusip no a    d   page  of  pages  i    a class of equity securities of the issuer becoming eligible for termination of registration pursuant to section g of the securities exchange act of  or j    any action similar to any of those enumerated above item  interest in securities of the issuer a    the fund is the record owner of the shares as the sole general partner of the fund the gp may be deemed to own beneficially the shares as the sole general partner of the gp the gpgp may be deemed to own beneficially the shares the management company may be deemed to own beneficially the shares pursuant to a management agreement between the fund and the management company as the controlling member and managing partner of the gpgp and as the controlling shareholder and managing partner of the management company uri geiger may be deemed to own beneficially the shares each reporting person disclaims beneficial ownership of the shares other than those shares which such person owns of record the percentage of outstanding common stock of the issuer which may be deemed to be beneficially owned by each reporting person is set forth on line  of such reporting persons cover sheet such percentage was calculated based on  shares of common stock reported to be outstanding immediately after the transactions b    regarding the number of shares as to which such person has i      sole power to vote or to direct the vote see line  of cover sheets ii     shared power to vote or to direct the vote see line  of cover sheets iii    sole power to dispose or to direct the disposition see line  of cover sheets iv    shared power to dispose or to direct the disposition see line  of cover sheets c    except as set forth in item  above none of the reporting persons has effected any transaction in the common stock during the last  days d    no other person is known to have the right to receive or the power to direct the receipt of dividends from or any proceeds from the sale of equity securities of the issuer beneficially owned by any of the reporting persons e    not applicable cusip no a    d   page  of  pages  item  contracts arrangements undertakings or relationships with respect to securities of the issuer see items   and  above and item  below all of which are incorporated in this item  by reference item  material to be filed as exhibits   exhibitnumber    exhibit description     joint filing agreement dated november   by and among the reporting persons     securities purchase agreement dated september   by and between cogentix medical inc and accelmed growth partners lp incorporated by reference to exhibit  to the current report on form k of cogentix medical inc filed with the securities and exchange commission on september       note exchange agreement dated september   by and between cogentix medical inc and lewis c pell incorporated by reference to exhibit  to the current report on form k of cogentix medical inc filed with the securities and exchange commission on september       voting agreement dated september   by and between accelmed growth partners lp and lewis c pell incorporated by reference to exhibit  to the current report on form k of cogentix medical inc filed with the securities and exchange commission on september       registration rights agreement dated november   by and among cogentix medical inc accelmed growth partners lp and lewis c pell incorporated by reference to exhibit  to the current report on form k of cogentix medical inc filed with the securities and exchange commission on november   cusip no a    d   page  of  pages  signature after reasonable inquiry and to the best of my knowledge and belief i certify that the information set forth in this statement is true complete and correct date november     accelmed growth partners lp by   accelmed growth partners gp lpby   accelmed growth partners agp ltd by   s uri geigername   uri geigertitle   managing partneraccelmed growth partners gp lp by   accelmed growth partners agp ltd by   s uri geigername   uri geigertitle   managing partneraccelmed growth partners agp ltd by   s uri geigername   uri geigertitle   managing partneraccelmed growth partners management ltd by   s uri geigername   uri geigertitle   managing partner s uri geigeruri geiger hedge fund resource center how to beat the market by  percentage points why track hedge funds download a free edition why you should dump your hedge funds  things you didnt know about hedge funds hot topics apple aapl latest stock news  company profile warren buffett news  analysis  portfolio  stock picks biggest insider purchases  sales news  analysis  data screener google goog latest stock news  company profile microsoft msft latest stock news  company profile home hedge funds markets blog authors about us contact us privacy policy terms of use site map all text and design is copyright  koala guide llc all rights reserved microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft accelmed  netfind content results aol search skip over navigation search the web web web content kids bike helmet  kids bike helmet  referencecom ad · referencecom​kids bike helmet find kids bike helmet and related articles search now browse education browse finance browse health browse vehicles kids bike helmet  amazoncom ad · amazoncom​sports save on kids bike helmet free day shipping w amazon prime amazoncom is rated rated  out of   reviews stx lacrosse heads  the most trusted lacrosse head ad · stxheadssportstopcom the most trusted lacrosse head price match guarantee ships free sportstopcom is rated rated  out of   reviews hawks helmet ad · nflshopcom​seattleseahawks licensed seattle seahawks helmets official hawks helmet your search for accelmed returned no results kids bike helmet  kids bike helmet  referencecom ad · referencecom​kids bike helmet find kids bike helmet and related articles search now browse education browse finance browse health browse vehicles kids bike helmet  amazoncom ad · amazoncom​sports save on kids bike helmet free day shipping w amazon prime amazoncom is rated rated  out of   reviews stx lacrosse heads  the most trusted lacrosse head ad · stxheadssportstopcom the most trusted lacrosse head price match guarantee ships free sportstopcom is rated rated  out of   reviews hawks helmet ad · nflshopcom​seattleseahawks licensed seattle seahawks helmets official hawks helmet searches related toaccelmed accelmed israel uri geiger accelmed accelmed growth partners valcare eximo medical accelmed llc valcare medical excelmed related searches accelmed israel uri geiger accelmed accelmed growth partners valcare eximo medical accelmed llc valcare medical excelmed search the web  aol inc all rights reservedprivacy   terms of use   preferences   contact us   powered by bing™ wowcom  part of the aol search network